D.C. Lung Cancer Conference 2023

Saturday, October 7, 2023, 7:30 AM - 5:30 PM, The Mayflower Hotel, Washington, DC

Registration is closed and will re-open onsite October 7, 2023 at the Mayflower Hotel, Washington, D.C.

This one-day conference will provide a comprehensive, multidisciplinary update on recent clinical advances in lung cancer. The field is evolving very rapidly and over the past year, there have been major shifts in our understanding of this highly lethal disease. We have seen high impact advances in all aspects of lung cancer management: from detection to diagnosis to treatment. The D.C. Lung Cancer Conference will emphasize current best practices for busy clinicians who care for patients with lung cancer, across disciplines. High impact, engaging didactic lectures will be delivered by international thought leaders and well-respected faculty in each field. An opening talk from a patient advocate will provide important perspective. There will be updates on CT screening, proper use of liquid biopsy, interpretation of molecular testing results and review of smoking cessation techniques. A section will be dedicated to optimizing multidisciplinary care for early stage and locally advanced lung cancer to include discussions on modern bronchoscopy, proton beam radiation, minimally invasive surgery and both neoadjuvant and adjuvant systemic therapy. Sessions with important updates on targeted therapy and immunotherapy will feature recognized experts in the field and there will be a debate over use of emerging biomarkers to guide treatment of advanced NSCLC. Attendees will have the opportunity to interact with faculty in frequent Q&A sessions with access to presentation materials for later review.

 

This Conference is endorsed by:

 

1. Identify the benefit of CT screening for lung cancer.
2. List the currently approved targeted options for patients with MET exon 14 mutant lung cancer.
3. Explain the approved use of targeted therapy for KRAS-mutant non-small cell lung cancer.
4. Describe the role of the patient advocate in clinical research.
5. Discuss the current application of liquid biopsy (or ctDNA analysis).
6. Debate the use of targeted therapy for patients with resected EGFR mutant non-small cell lung cancer.
7. Explain the toxicity associated with targeted therapy given after immunotherapy in EGFR mutant non-small cell lung cancer.
8. Explain the approved adjuvant and neoadjuvant treatment options for resectable, driver negative non-small cell lung cancer.
9. Explain the significance and use of patient centered communications on the patient and family experience.
10. Summarize strategies for navigating conversations with patients and families.
11. Discuss standard targeted agents in use for patients with ALK-positive non-small cell lung cancer.
12. Discuss management of immune-mediated toxicities.
13. Describe the benefit of immunotherapy in the treatment of small cell lung cancer.
14. Describe the approved use of tumor treating fields.
15. Identify nursing strategies for early detection of immune-mediated toxicities.
16. Recognize unique toxicities associated with targeted agents used in NSCLC.
17. Describe current standard care for advanced mesothelioma.
18. Discuss standard initial therapy for advanced small cell lung cancer (SCLC).
19. Identify the roles and responsibilities of members of the healthcare team involved in the collaborative care of patients with lung cancer.
20. Integrate a team-based approach in the care of patients with lung cancer.

Advance Purchase and Onsite Rate August 7 to October 7

• Physician $200
• IASLC Member $140
• Resident/Fellow $0
• Physician Assistant $125
• Nurse Practitioner $125
• Nurse $125
• Pharmacist $125
• Allied Health Professional $125
• Patient Advocate $100
• Industry Professional  $275

Please contact [email protected] or (833) 731-1273 for registration assistance

 In support of improving patient care, MedStar Health is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.

 

Credit Designation Statement

This activity was planned by and for the healthcare team and learners will receive 6.75 Interprofessional Continuing Education (IPCE) credits for learning and change.

 

 

Physicians: MedStar Health designates this live activity for a maximum of 6.75 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity. 

American Board of Internal Medicine MOC Credit

Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 6.75 MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

MOC Participation Threshold

Learner participates by writing a reflective statement and makes a commitment to change or maintain an element of practice.

Nurses: This activity is approved for 6.75 ANCC contact hours. Nurses should claim only the credit commensurate with the extent of their participation in the activity.

Pharmacists: This activity is approved for 6.75 contact hours. This learning activity is knowledge-based. The Universal Activity Number for this program is UAN# JA4008151-0000-23-030-L05-P.

AMA PRA Category 1 Credits™ Physician (6.75 hours), ABIM MOC Part 2 (6.75 hours), IPCE (6.75 hours), Non-Physician Member of the Healthcare Team (6.75 hours), Nurse - ANCC (6.75 hours), Pharmacist - ACPE (6.75 hours)

The Mayflower Hotel

1127 Connecticut Ave NW

Washington, DC 20036

Hotel arrangements can be made online at: book.passkey.com/go/MedstarHealth2023

Hotel Cutoff Date: September 8, 2023

Mitigation of Relevant Financial Relationships

MedStar Health adheres to the ACCME’s Standards for Integrity and Independence in Accredited Continuing Education.

 
Individuals in a position to control the content of this CE activity, including faculty, planners, reviewers, or others are required to disclose all relevant financial relationships with ineligible companies. An ineligible company is any entity whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients. All of the relevant financial relationships listed below have been mitigated prior to the commencement of the activity.

Saturday, October 7, 2023

If you are interested in supporting the program, please contact Elizabeth Romano at [email protected]